Biological product for preventing novel coronavirus

A coronavirus, biological product technology, applied in the direction of viruses, medical preparations containing active ingredients, microorganisms, etc., can solve problems such as affecting the immune response and affecting the integrity of virus antigens

Inactive Publication Date: 2020-06-05
SYNO SHENZHEN BIOMEDICAL RES CO LTD
View PDF1 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The preparation of traditional attenuated or inactivated vaccines requires live virus strains, and the attenuated or inactivated process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological product for preventing novel coronavirus
  • Biological product for preventing novel coronavirus
  • Biological product for preventing novel coronavirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Construction of recombinant adenovirus vector gene vaccine seed expressing S1 protein antigen

[0034] Use IDT's codon optimization software to optimize the S1 protein gene sequence of the new coronavirus (GenBank: MN908947.3) to increase the protein expression rate in the human body. The optimized nucleotide sequence is shown in SEQ ID NO.1. The gene fragment of the S1 protein was ordered from the American IDT company. Gene sequencing verified the correctness of the gene sequence.

[0035] In order to achieve rapid and high-quantity expression of S1 protein, the S1 protein gene expression cassette uses the CMV promoter and adds the Kozak sequence. SV40 polyA sequence is used to ensure correct protein expression. Using conventional molecular biology methods and reagents, clone and construct a complete S1 protein gene expression cassette. in figure 2 A schematic diagram of the S1 protein gene expression cassette is shown in.

[0036] The nucleotide sequence of t...

Embodiment 2

[0040] Example 2 Construction of recombinant adenovirus vector gene vaccine seeds expressing S1 protein antigen and N protein antigen simultaneously

[0041] Use IDT's codon optimization software to optimize the S1 protein gene sequence and N protein gene sequence (GenBank: MN908947.3) of the new coronavirus to increase the protein expression rate in the human body. The optimized S1 nucleotide sequence is shown in SEQ ID NO.1, and the N nucleotide sequence is shown in SEQ ID NO.2. In order to achieve the equivalent expression of S1 protein antigen and N protein antigen at the same time, a gene expressing a T2A cleavable polypeptide was added between the S1 protein gene and the N protein gene to form a composite gene fragment expressing S1 protein and N protein. Gene fragments expressing S1 protein and N protein were synthesized by ordering genes from IDT Corporation of the United States. Gene sequencing verified the correctness of the gene sequence.

[0042] In order to achieve r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a biological product for preventing novel coronavirus (COVID-19). The biological product can be a gene vaccine or gene medicine, wherein the gene vaccine adopts a human type-5adenovirus with deletion of E1 and E3 genes as a vector for carrying an S1 protein antigen for expressing a Spike S1 subunit of the novel coronaviruses or simultaneously carrying an S1 expression protein antigen and N protein antigen. Through in-vivo expression of antigen proteins, the immune reaction of a body upon the novel coronavirus can be stimulated, and the effect of preventing infection and propagation of the novel coronavirus.

Description

Technical field [0001] The invention belongs to the technical field of biopharmaceutical products, and relates to biological products for the prevention of new coronaviruses. It uses gene synthesis, codon optimization, and gene cloning to construct recombinant adenovirus vector gene vaccines, and is used to develop new coronaviruses (COVID-19) prevention Gene vaccine products. Background technique [0002] The outbreak of the new type of coronavirus (COVID-19) has brought a huge crisis to the public health of the society. The infection is very contagious and has caused huge social health and economic impacts on human beings. It is highly valued by people and has not yet been effective. Treatment methods and preventive vaccines. For the health of the people and the safety of the country and society, there is an urgent need to develop a vaccine that can prevent new coronavirus infections. [0003] Commonly used virus vaccine development methods include 1) inactivated virus vaccine,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/215A61K48/00A61P31/14A61P11/00
CPCA61K39/12A61K48/005A61K2039/53A61P11/00A61P31/14C12N2770/20034
Inventor 张书元徐卫
Owner SYNO SHENZHEN BIOMEDICAL RES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products